Recognition that neurohormonal activation plays a central role in the pathogenesis of heart
failure (HF) led to the development of angiotensin converting enzyme inhibitors (ACEIs) …

Angiotensin-converting enzyme inhibitors (ACEIs) have been the cornerstone of treatment of
heart failure with reduced ejection fraction (HFrEF) for over two decades. Inhibition of …

Abstract Objectives: The PARAGON-HF (Prospective Comparison of ARNI with ARB Global
Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy …

Composite angiotensin receptor-neprilysin inhibition (ARNi) represents a novel
pharmacologic strategy for treatment of heart failure with reduced ejection fraction (HFrEF) …

Heart failure (HF) is a multi-faceted clinical condition affecting up to 2% of the population in
the developed world and is linked to significant morbidity and mortality, therefore posing a …

This article provides a contemporary review and a new perspective on the role of neprilysin
inhibition in heart failure (HF) in the context of recent clinical trials and addresses potential …

Heart failure (HF) accounts for a tremendous burden on health care systems and the society.
Since the landmark PARADIGM-HF trial, sacubitril/valsartan, the first in the class of …

Aims Although the focus of therapeutic intervention has been on neurohormonal pathways
thought to be harmful in heart failure (HF), such as the renin–angiotensin–aldosterone …

Sacubitril/valsartan is a novel, first-in-class drug, which combines a neprilysin inhibitor with
an angiotensin receptor blocker. Sacubitril inhibits neprilysin endopeptidase, blocking the …

Dual angiotensin and neprilysin inhibition using the combination drug sacubitril–valsartan
has ushered in a new era in the treatment of heart failure (HF). The randomized controlled …